Prognostic Factors in Malignant Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: A Baseline Risk Score

被引：0
|
作者：
Guijosa, A. [1 ]
Munoz-Montano, W. [1 ]
Trejo-Rosales, R. [2 ]
Gomez-Garcia, A. P. [1 ]
Cabrera-Miranda, L. A. [1 ]
Flores, D. [1 ]
Arrieta, O. [1 ]
机构：
[1] Natl Canc Inst Mexico INCan, Mexico City, DF, Mexico
[2] Natl Med Ctr, Century XXI, IMSS, Mexico City, DF, Mexico
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Mesothelioma; Prognosis; Chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.14A.02
引用
收藏
页码：S684 / S684
页数：1
相关论文
共 50 条
  • [41] Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically
    Rusch, VW
    Venkatraman, ES
    ANNALS OF THORACIC SURGERY, 1999, 68 (05): : 1799 - 1804
  • [42] Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
    Bille, Andrea
    Krug, Lee M.
    Woo, Kaitlin M.
    Rusch, Valerie W.
    Zauderer, Marjorie G.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : 249 - 255
  • [43] Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)
    Cedres, S.
    Amair, F.
    Martinez-Marti, A.
    Navarro, A.
    Pardo, N.
    Remon-Masip, J.
    Miquel, J. M.
    Villacampa, G.
    Dienstmann, R.
    Felip Font, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S131 - S132
  • [44] Tumor treating fields plus chemotherapy for first-line malignant pleural mesothelioma (MPM): Radiological responses in the STELLAR trial
    Grosso, F.
    Ceresoli, G. L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia
    Lee, Christopher W.
    Murray, Nevin
    Anderson, Helen
    Rao, Sanjay C.
    Bishop, Winston
    LUNG CANCER, 2009, 64 (03) : 308 - 313
  • [46] Tumor Treating Fields plus chemotherapy for first-line treatment of malignant pleural mesothelioma: Final Results of the STELLAR Trial
    Ceresoli, G.
    Aerts, J.
    Madrzak, J.
    Dziadziuszko, R.
    Ramlau, R.
    Cedres, S.
    Hiddinga, B.
    Van Meerbeeck, J. P.
    Mencoboni, M.
    Planchard, D.
    Chella, A.
    Krzakowski, M.
    Crino, L.
    Grosso, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 230 - 231
  • [47] A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
    Banna, Giuseppe Luigi
    Addeo, Alfredo
    Zygoura, Panagiota
    Tsourti, Zoi
    Popat, Sanjay
    Curioni-Fontecedro, Alessandra
    Nadal, Ernest
    Shah, Riyaz
    Pope, Anthony
    Fisher, Patricia
    Spicer, James
    Roy, Amy
    Gilligan, David
    Gautschi, Oliver
    Janthur, Wolf-Dieter
    Lopez-Castro, Rafael
    Roschitzki-Voser, Heidi
    Dafni, Urania
    Peters, Solange
    Stahel, Rolf A.
    LUNG CANCER, 2022, 169 : 77 - 83
  • [48] New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
    Laune, Quentin
    Brosseau, Solenn
    BULLETIN DU CANCER, 2022, 109 (01) : 4 - 6
  • [49] Complement score: A novel prognostic tool in malignant pleural mesothelioma?
    Balduit, Andrea
    Mangogna, Alessandro
    Vaira, Valentina
    Agostinis, Chiara
    Raviele, Paola Rafaniello
    Bottin, Cristina
    Salton, Francesco
    Nesa, Francesco
    Fusco, Nicola
    Ferrero, Stefano
    Zanconati, Fabrizio
    Confalonieri, Marco
    Bulla, Roberta
    IMMUNOBIOLOGY, 2023, 228 (05) : 78 - 78
  • [50] Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma
    Fennell, DA
    Steele, JPC
    Shamash, J
    Sheaff, MT
    Evans, MT
    Goonewardene, TI
    Nystrom, ML
    Gower, NH
    Rudd, RM
    LUNG CANCER, 2005, 47 (02) : 277 - 281
12345